OncoCrest: AI Powered Predictive Platform for Precision Oncology by Rayca Precision

Products / Solutions

Information

OncoCrest is a cutting-edge artificial intelligence predictive service that helps oncologists personalize cancer treatment and optimize patient outcomes. By analyzing the molecular characteristics of unknown primary tumors and the clinical and molecular factors of the patient, OncoCrest can accurately identify the type and stage of the tumor, predict its clinical consequences and aggressiveness, and select the most effective FDA approved treatments. Additionally, OncoCrest's survival prediction model allows oncologists to compare the success probability of different treatment options, enabling them to choose the approach that has the highest likelihood of success for their patients. By providing oncologists with actionable insights and evidence-based decision making tools, OncoCrest is transforming the way cancer is treated and improving patient outcomes.
Rayca PrecisionRayca Precision, founded in mid-2022, excels in delivering advanced bioinformatics and machine learning solutions for precision medicine. Rayca’s unique approach includes a Secure Research Environment (SRE) that upholds stringent data integrity and confidentiality standards, facilitating seamless data collaborations without the data ever leaving the owner's cloud aiming to dismantle data silos, maximizing healthcare data utility. Rayca’s platforms processes diverse genomic and health data types holistically, facilitating personalized patient care and advancing drug discovery research. Bootstrapped to date, we are preparing to seek seed funding in 2 months. At EMERGE 2050 and PMES in Dubai, we seek investors and market partners to further our impact in healthcare innovation and data-enabled precision medicine.

Join the event!